Volume 13, Number 4 (May/Jun 2022)

Editorial

Do You Employ Shared Decision-Making in Your Practice?

Editor-in-Chief Beth Faiman discusses how shared decision-making is an important component of any patient-centered encounter, and reviews a tool to help advanced practitioners incorporate these strategies into visits.

May 12, 2022

Research and Scholarship

Evaluation of Emergency Department Visits by Oncology Patients: A Running Comparison to Admissions and ED Visits Under the CMS OP-35 Ruling

Background: Cancer is the second leading cause of death in the United States. The incidence of emergency department (ED) visits by oncology patients has grown over the past years. Some ED visits are medically unnecessary and could be pre...

May 16, 2022

Research and Scholarship

Implementing a Clinical Decision Tool to Improve Oncologic Venous Thromboembolism Management

Background: Cancer patients with venous thromboembolic (VTE) disease are complex, and many factors must be considered when initiating anticoagulation management. Clinical decision support systems can aid in decision-making by utilizing g...

May 16, 2022

Review Article

Practical Management of the Venetoclax-Treated Patient in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia

Venetoclax is a potent oral, highly selective small-molecule inhibitor of the antiapoptotic B-cell lymphoma 2 protein approved for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma in treatment-naive patients (in combinati...

May 18, 2022

Review Article

Practical Strategies for Advanced Practitioners Streamlining the Integration of Oncology Biosimilar Therapies Into Practice

In oncology practices across the United States, biosimilars—highly similar versions of licensed, innovator (reference) biological medicines—are currently emerging as more affordable therapeutic options. Only after a rigorous product deve...

May 18, 2022

Practice Matters

COVID-19 Vaccine Effectiveness in Oncology Patients

Oncology patients are at greater risk of morbidity and mortality from coronavirus disease 2019 (COVID-19) infection than the general population. Patients with malignancies were prioritized in vaccine distribution to confer protection to ...

May 18, 2022

Prescriber's Corner

Encorafenib and Binimetinib Combination Therapy in Metastatic Melanoma

The treatment landscape for metastatic melanoma has changed dramatically over the past few years as new medications have been developed. Encorafenib, a B-Raf protein kinase inhibitor, and binimetinib, a MEK inhibitor, were approved by th...

May 18, 2022